LIST OF TABLES

		Page No.
Table 2.1	Small molecules and macromolecules currently being studied for nasal delivery	19
Table 2.2	Pharmacopoeial specifications for chitosan	42
Table 2.3	Typical viscosity (dynamic) values for chitosan 1% w/v solutions in different acids	44
Table 2.4	Pharmacopeial specifications for sodium alginate	47
Table 2.5	Uses of sodium alginate	50
Table 3.1	Calibration data for Carvedilol in pH 6.2 phosphate buffer and methanol (9:1)	70
Table 3.2	Parameters for UV spectrometric method of analysis for Carvedilol in pH 6.2 phosphate buffer and methanol (9:1)	71
Table 3.4	Interday variability of Carvedilol assay in pH 6.2 phosphate buffer and methanol (9:1) by UV spectroscopy over three consecutive days	72
Table 3.5	Calibration data for Carvedilol in methanol and 0.1N HCl (3:2)	73
Table 3.6	Parameters for UV spectrometric method of analysis for Carvedilol in methanol and 0.1N HCl (3:2).	74
Table 3.7	Intraday precision and accuracy for the Carvedilol assay in methanol and 0.1N HCl (3:2) by UV spectroscopy	74
Table 3.8	Interday variability of Carvedilol assay in methanol and 0.1N HCl (3:2) by UV spectroscopy over three consecutive days	75
Table 3.9	Calibration data for Nitrendipine in pH 6.2 phosphate buffer containing 1% Tween 80	77
Table 3.10	Parameters for UV spectrometric method of analysis for Nitrendipine in pH 6.2 phosphate buffer containing 1% Tween 80	78
Table 3.11	Intraday precision and accuracy for the Nitrendipine assay in pH 6.2 phosphate buffer containing 1% Tween 80 by UV spectroscopy	78
Table 3.12	Interday variability of Nitrendipine assay in pH 6.2 phosphate buffer containing 1% Tween 80 by UV spectroscopy over three	79

	consecutive days	
Table 3.13	Calibration data for Nitrendipine in methanol and 0.1N HCl (3:2)	80
Table 3.14	Parameters for UV spectrometric method of analysis for Nitrendipine in methanol and 0.1N HCl (3:2).	81
Table 3.15	Intraday precision and accuracy for the Nitrendipine assay in methanol and 0.1N HCl (3:2) by UV spectroscopy	81
Table 3.16	Interday variability of Nitrendipine assay in methanol and 0.1N HCl (3:2) by UV spectroscopy over three consecutive days	82
Table 4.1	Different batches of chitosan microspheres	87
Table 4.2	Various formulation parameters used in the preparation of CRV loaded microspheres	97
Table 4.3	Characteristics of prepared CRV loaded chitosan microspheres	98
Table 4.4	Constants for Langmuir and Freundlich Equations	104
Table 4.5	Kinetic model of Carvedilol release from chitosan microspheres	107
Table 4.6	Release mechanisms of different formulations	108
Table 4.7	Stability study results for CRV loaded chitosan microspheres under accelerated condition	113
Table 5.1	Factorial design parameters and experimental conditions	119
Table 5.2	Formulation of the microspheres utilizing 2^3 factorial design	122
Table 5.3	Flow properties of CRV loaded Alginate microspheres	124
Table 5.4	Kinetic model of Carvedilol release from Alginate microspheres	130
Table 5.5	Release kinetics parameters and mechanisms of different formulations	131
Table 5.6	Summary of results of regression analysis for responses Y1 and Y2	132
Table 5.7	Results of analysis of variance for measured response	132
Table 5.8	The predicted and observed response variables of the sodium alginate microspheres	141
Table 5.9	Stability study results for CRV loaded Alginate microspheres under accelerated condition	145

Table 6.1	Various formulation parameters used in the preparation of NTD loaded microspheres	151
Table 6.2	Characteristics of prepared NTD loaded chitosan microspheres	152
Table 6.3	Constants for Langmuir and Freundlich Equations	159
Table 6.4	Kinetic model of Carvedilol release from chitosan microspheres	162
Table 6.5	Release mechanisms of different formulations	163
Table 6.6	Stability study results for CRV loaded chitosan microspheres under accelerated condition	168
Table 7.1	Factorial design parameters and experimental conditions	173
Table 7.2	Formulation of the microspheres utilizing 2^3 factorial design	176
Table 7.3	Characteristics of prepared NTD loaded Alginate microspheres	179
Table 7.3	Kinetic model of Nitrendipine release from Alginate microspheres	184
Table 7.4	Release kinetics parameters and mechanisms of different formulations	185
Table 7.5	Summary of results of regression analysis for responses Y1 and Y2	186
Table 7.6	Results of analysis of variance for measured response	186
Table 7.7	The predicted and observed response variables of the sodium alginate microspheres	195
Table 7.8	Stability study results for NTD loaded Alginate microspheres under accelerated condition	199
Table 8.1	Percent of formulation delivered from MIAT® nasal monodose insufflator with 5 mg loading	207
Table 8.2	Percent of formulations delivered from MIAT® nasal monodose insufflator with 10 mg loading	207
Table 8.3	Percent of formulation delivered from MIAT® nasal monodose insufflator with 20 mg loading	208
Table 9.1	Effect of pH on the % radiolabeling efficiency of Microspheres and Carvedilol	219
Table 9.2	Effect of Incubation time on the % radiolabeling efficiency of Microspheres and Carvedilol	219

Table 9.3	Effect of Stannous Chloride Concentration on the % radiolabeling efficiency of Microspheres and Carvedilol	220
Table 9.4	In Vitro Stability of the ^{99m}Tc-CRV and ^{99m}Tc-Microspheres in Physiological Saline at 37 ^{0}C	221
Table 9.5	In Vitro Stability of the ^{99m}Tc-CRV and ^{99m}Tc-Microspheres in Serum at 37 ^{0}C	221
Table 9.6	Mean blood radioactivity (KCPM/gm) of Carvedilol after IV and of CHCR and ALCR after Intranasal administration	222
Table 9.7	Pharmacokinetic parameters of Carvedilol after IV and of CHCR and ALCR after Intranasal administration in Rabbits	224
Table 9.8	The radioactivity remaining in the rabbit nasal cavity at each time point after administering chitosan microspheres (CHCR), alginate microspheres (ALCR) and lactose powder (control)	227
Table 10.1	Effect of pH on the % radiolabeling efficiency of Microspheres and Nitrendipine	237
Table 10.2	Effect of Incubation time on the % radiolabeling efficiency of Microspheres and Nitrendipine	238
Table 10.3	Effect of Stannous Chloride Concentration on the % radiolabeling efficiency of Microspheres and Nitrendipine	239
Table 10.4	In Vitro Stability of the ^{99m}Tc-NTD and ^{99m}Tc-Microspheres in Physiological Saline at 37 ^{0}C	239
Table 10.5	In Vitro Stability of the ^{99m}Tc-NTD and ^{99m}Tc-Microspheres in Serum at 37 ^{0}C	240
Table 10.6	Mean blood radioactivity (KCPM/gm) of Nitrendipine after IV and of CHNT and ALNT after Intranasal administration	241
Table 10.7	Pharmacokinetic parameters of Nitrendipine after IV and of CHNT and ALNT after Intranasal administration in Rabbits	243
Table 10.8	The radioactivity remaining in the rabbit nasal cavity at each time point after administering chitosan microspheres (CHNT), alginate microspheres (ALNT) and lactose powder (control)	245